Clinical Nuclear Medicine

Skip Navigation LinksHome > September 2013 - Volume 38 - Issue 9 > New Treatment Option: 223Ra Chloride, the First Approved Un...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182a2dd53
Interesting Images

New Treatment Option: 223Ra Chloride, the First Approved Unsealed α-Emitting Radiopharmaceutical

Colletti, Patrick M. MD

Collapse Box


Abstract: A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration–approved unsealed α-emitting radiopharmaceutical.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.